HonCode

Go Back   HER2 Support Group Forums > Articles of Interest
Register Gallery FAQ Members List Calendar Search Today's Posts Mark Forums Read

Reply
 
Thread Tools Display Modes
Old 03-30-2004, 12:23 AM   #1
Paul
Guest
 
Posts: n/a
CAMBRIDGE Mass.--(BUSINESS WIRE)--March 30 2004--ARIAD Pharmaceuticals Inc. (Nasdaq: ARIA) today announced results of preclinical studies showing that its lead mTOR inhibitor AP23573 augments the anti-cancer activity of widely used cytotoxic and new anti-cancer agents when given in combination. Included in the studies are the molecularly targeted drugs imatinib (Gleevec(TM)) trastuzumab (Herceptin(R)) and an EGFR inhibitor as well as the chemotherapy drugs docetaxel doxorubicin cisplatin and topotecan. Phase 1 clinical trials of AP23573 in patients with advanced cancers are currently underway and phase 2 studies are expected to begin in second quarter 2004.
  Reply With Quote
Reply

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is On

Forum Jump


All times are GMT -7. The time now is 02:05 AM.


Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021
free webpage hit counter